Valuation: Control Bionics Limited

Market Cap 3.05Cr 2.11Cr 1.85Cr 1.7Cr 1.58Cr 3Cr 201.31Cr 20Cr 7.93Cr 99Cr 7.94Cr 7.77Cr 340.98Cr P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 3.02Cr 2.1Cr 1.83Cr 1.69Cr 1.57Cr 2.98Cr 199.74Cr 20Cr 7.87Cr 98Cr 7.87Cr 7.71Cr 338.33Cr EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
47.41%
Yield 2024 *
-
Yield 2025 -
1 day-0.67%
1 week-9.76%
1 month+5.71%
3 months+23.33%
6 months+21.31%
Current year+21.31%
1 week 0.07
Extreme 0.071
0.09
1 month 0.07
Extreme 0.071
0.1
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.74
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 19/01/2023
Director of Finance/CFO - 13/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman 66 19/11/2025
Director/Board Member - 19/01/2023
Director/Board Member - 01/04/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.67%-9.76%+131.25%-14.94% 2.11Cr
-1.95%+1.16%+3.42%-29.47% 1.64TCr
+5.89%+23.51%+46.13%+98.40% 178.4Cr
+0.39%+32.34%-39.55%-78.08% 124.45Cr
+0.06%+3.85%-28.16%+33.46% 113.81Cr
+1.31%+4.95%-25.50%-53.22% 64Cr
+0.21%+3.42%-36.59%-57.01% 58Cr
-0.66%+3.11%+20.57%-55.49% 45Cr
+1.79%+0.16%-55.21%-60.69% 38Cr
+2.52%+7.65%-20.43%-19.03% 36Cr
Average +0.89%+5.88%-0.41%-23.61% 229.61Cr
Weighted average by Cap. -0.81%+4.50%+0.13%-21.26%

Financials

2024 2025
Net sales 53.51L 37.11L 32.44L 29.81L 27.79L 52.71L 35Cr 3.58Cr 1.39Cr 17Cr 1.39Cr 1.36Cr 60Cr 61.45L 42.62L 37.26L 34.24L 31.91L 60.53L 41Cr 4.11Cr 1.6Cr 20Cr 1.6Cr 1.57Cr 69Cr
Net income -59.14L -41.01L -35.85L -32.95L -30.71L -58.25L -39Cr -3.96Cr -1.54Cr -19Cr -1.54Cr -1.51Cr -66Cr -61.09L -42.37L -37.04L -34.04L -31.73L -60.17L -40Cr -4.09Cr -1.59Cr -20Cr -1.59Cr -1.56Cr -68Cr
Net Debt -96.95T -67.23T -58.78T -54.02T -50.35T -95.5T -64.02L -6L -3L -31.47L -3L -2L -1.08Cr -2L -2L -1L -1L -1L -2L -1.57Cr -15.87L -6L -77.01L -6L -6L -2.65Cr
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
03/26/03 A$0.0740 -0.67% 79,459
02/26/02 A$0.0745 +3.47% 1,78,494
01/26/01 A$0.0720 -2.70% 8,37,811
30/26/30 A$0.0740 -5.13% 6,30,575
29/26/29 A$0.0780 -4.88% 4,99,206

Annual profits - Rate of surprise